Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Harold E Bays1 Louisville Metabolic & Atherosclerosis Research Center (L-MARC), Louisville, KY, USA

Eliot A Brinton2 Utah Foundation for Biomedical Research, Salt Lake City, UT, USA

Joseph Triscari3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Erluo Chen3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Darbie Maccubbin3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Alexandra A MacLean3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Kendra L Gibson3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Rae Ann Ruck3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Amy O Johnson-Levonas3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Edward A O’Neill3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Yale B Mitchel3 Merck & Co, Inc., Whitehouse Station, NJ, USACorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.